Vaxxas secures equity funding of $20 million to further needle-free vaccine delivery system

Biotech startup Vaxxas has secured equity funding of $20 million from new and existing investors to advance a series of clinical programs for major diseases.

The company, based in Cambridge, Massachusetts, and Queensland, Australia, will use the funds to advance a series of clinical programs and develop a pipeline of new vaccine products for major diseases using Vaxxas’ patented Nanopatch platform. Vaxxas has now raised $33 million in total.

David Hoey, president and chief executive of Vaxxas, said: “As we have advanced the development of our Nanopatch needle-free vaccination technology, we have seen tremendous opportunities to create our own proprietary pipeline of Nanopatch-based vaccine products as well as those with partners. This funding creates an important inflection point for Vaxxas, as we are now poised to create significantly increased value through our first clinical studies.”